Cerebrospinal hypocretin, daytime sleepiness and sleep architecture in Parkinson's disease dementia

Brain

Volumn 132, Issue 12, 2009, Pages 3308-3317

  Compta, Yaroslau ^a   Santamaria, Joan ^a   Ratti, Luca ^a   Tolosa, Eduardo ^a   Iranzo, Alex ^a   Muñoz, Esteban ^a   Valldeoriola, Francesc ^a   Casamitjana, Roser ^a   Ríos, Jose ^a   Marti, Maria J ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Dementia; Excessive daytime sleepiness; Hypocretin 1; Parkinson's disease; Sleep architecture

Indexed keywords

OREXIN;

ADULT; AGED; ARTICLE; CEREBROSPINAL FLUID LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DAYTIME SOMNOLENCE; DEMENTIA; DISEASE SEVERITY; EPWORTH SLEEPINESS SCALE; FEMALE; HUMAN; HYPOTHALAMUS; MALE; MINI MENTAL STATE EXAMINATION; PARKINSON DISEASE; POLYSOMNOGRAPHY; PRIORITY JOURNAL; SLEEP; VIDEORECORDING;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CIRCADIAN RHYTHM; DISORDERS OF EXCESSIVE SOMNOLENCE; DOMINANCE, CEREBRAL; FEMALE; HUMANS; HYPOTHALAMUS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LEWY BODY DISEASE; MALE; MIDDLE AGED; NEUROPEPTIDES; OCCIPITAL LOBE; PARKINSON DISEASE; POLYSOMNOGRAPHY; PREDICTIVE VALUE OF TESTS; SLEEP; SPINAL PUNCTURE;

EID: 72649095340     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awp263     Document Type: Article

References (56)

1. American Psychiatric Association.edn. Diagnostic and statistical manual of mental disorders. 4th edn., Washington: American Psychological Association; 2000.
2. Arnulf I, Konofal E, Merino-Andreu M, Houeto JL, Mesnage V, Welter ML, et al. Parkinson's disease and sleepiness: an integral part of PD. Neurology 2002; 58: 1019-1024
3. Arnulf I, Bonnet AM, Damier P, Bejjani BP, Seilhean D, Derenne JP, et al. Hallucinations, REM sleep, and Parkinson's disease: a medical hypothesis. Neurology 2000; 55: 281-288
4. Baumann C, Ferini-Strambi L, Waldvogel D, Werth E, Bassetti CL. Parkinsonism with excessive daytime sleepiness: a narcolepsy-like disorder? J Neurol 2005; 252: 139-145
5. Baumann CR, Scammell TE, Bassetti CL,. Parkinson's disease, sleepiness and hypocretin/orexin. Brain 2007; 131: e91.
6. Barbanoj MJ, Romero S, Morte A, Giménez S, Lorenzo JL, et al. Sleep laboratory study on single and repeated dose effects of paroxetine, alprazolam and their combination in healthy young volunteers. Neuropsychobiology 2005; 51: 134-147
7. Begg C, Cho M, Eastwood S, Horton R, Mother D, Olkin I, et al. Improving the quality of reporting of randomized controlled trials: the CONSORT statement. JAMA 1996; 276: 637-639
8. Bell C, Wilson S, Rich A, Bailey J, Nutt D. Effects on sleep architecture of pindolol, paroxetine and their combination in healthy volunteers. Psychopharmacology 2003; 166: 102-110
9. Boddy F, Rowan EN, Lett D, O'Brien JT, McKeith IG, Burn DJ. Subjectively reported sleep quality and excessive daytime somnolence in Parkinson's disease with and without dementia, dementia with Lewy bodies and Alzheimer's disease. Int J Geriatr Psychiatry 2007; 22: 529-535
10. Bonanni L, Thomas A, Tiraboschi P, Perfetti B, Varanese S, Onofrj M. EEG comparisons in early Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease with dementia patients with a 2-year follow-up. Brain 2008; 131: 690-705.
11. Cohrs S, Rodenbeck A, Guan Z, Pohlmann K, Jordan W, Meier A, et al. Sleep-promoting properties of quetiapine in healthy subjects. Psychopharmacology 2004; 174: 421-429 (Pubitemid 39044301)
12. Diederich NJ, Vaillant M, Mancuso G, Lyen P, Tiete J. Progressive sleep 'destructuring' in Parkinson's disease. A polysomnographic study in 46 patients. Sleep Med 2005; 6: 313-318 (Pubitemid 40867821)
13. Domitrz I, Friedman A. Electroencephalography of demented and non-demented Parkinson's disease patients. Parkinsonism Relat Disord 1999; 5: 37-41.
14. Drouot X, Moutereau S, Nguyen JP, Lefaucheur JP, Créange A, Remy P, et al. Low levels of ventricular CSF orexin/hypocretin in advanced PD. Neurology 2003; 61: 540-543
15. Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 2007; 22: 1689-1707 (Pubitemid 47597592)
16. Emser W, Brenner M, Stober T, Schimrigk K. Changes in nocturnal sleep in Huntington's and Parkinson's disease. J Neurol 1988; 235: 177-179
17. Fahn S, Elton RL. members of the UPDRS Development Committee Unified Parkinson's Disease rating Scale. Unified Parkinson's Disease rating Scale. In: Fahn S, Marsden CD, Calne DB, Lieberman A, editors. Recent developments in Parkinson's disease. Florham Park, NJ: McMillan Health Care Information; 1987. p. 153-163
18. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental state." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198
19. Fogelson N, Kogan E, Korczyn AD, Giladi N, Shabtai H, Neufeld MY. Effects of rivastigmine on the quantitative EEG in demented Parkinsonian patients. Acta Neurol Scand 2003; 107: 252-255
20. Fronczek R, Overeem S, Lee SY, Hegeman IM, van Pelt J, van Duinen SG, et al. Hypocretin (orexin) loss in Parkinson's disease. Brain 2007; 130: 1577-1585
21. Fronczek R, Overeem S, Lee SY, Hegeman IM, van Pelt J, van Duinen SG, et al. Hypocretin (orexin) loss and sleep disturbances in Parkinson's Disease. Brain 2008; 131: e88.
22. Gerashchenko D, Murillo-Rodriguez E, Lin L, Xu M, Hallett L, Nishino S, et al. Relationship between CSF hypocretin levels and hypocretin neuronal loss. Exp Neurol 2003; 184: 1010-1016
23. Gjerstad MD, Aarsland D, Larsen JP. Development of daytime somnolence over time in Parkinson's disease. Neurology 2002; 58: 1544-1546
24. Gjerstad MD, Alves G, Wentzel-Larsen T, Aarsland D, Larsen JP. Excessive daytime sleepiness in Parkinson disease: is it the drugs or the disease? Neurology 2006; 67: 853-858
25. Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord 2008; 23: 837-844
26. Hilker R, Thomas AV, Klein JC, Weisenbach S, Kalbe E, Burghaus L, et al. Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways. Neurology 2005; 65: 1716-1722
27. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967; 17: 427-442
28. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181-184
29. Iber C, Ancoli-Israel S, Chesson A, Quan SF, for the American Academy of Sleep Medicine.The AASM Manual for the Scoring of Sleep and Associated Events. Rules, Terminology and Technical Specifications. Westchester, IL: American Academy of Sleep Medicine; 2007.
30. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991; 14: 540-545
31. Littner MR, Kushida C, Wise M, Davila DG, Morgenthaler T, Lee-Chiong T, et al. Practice parameters for clinical use of the multiple sleep latency test and the maintenance of wakefulness test. Sleep 2005; 28: 113-121
32. Maeda T, Nagata K. Parkinson's disease comorbid with narcolepsy presenting low CSF hypocretin/orexin level. Sleep Med 2006; 7: 662.
33. Martinez-Rodriguez JE, Lin L, Iranzo A, Genis D, Marté MJ, Santamaria J, et al. Decreased hypocretin-1 (Orexin-A) levels in the cerebrospinal fluid of patients with myotonic dystrophy and excessive daytime sleepiness. Sleep 2003; 26: 287-290
34. Martinez-Rodriguez JE, Seppi K, Cardozo A, Iranzo A, Stampfer-Kountchev M, Wenning G, et al. SINBAR (Sleep Innsbruck Barcelona) group. Cerebrospinal fluid hypocretin-1 levels in multiple system atrophy. Mov Disord 2007; 22: 1822-1824.
35. Mignot E, Lammers GJ, Ripley B, Okun M, Nevsimalova S, Overeem S, et al. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol 2002; 59: 1553-1562
36. Mito Y, Yoshida K, Yabe I, Makino K, Hirotani M, Tashiro K, et al. Brain 3D-SSP SPECT analysis in dementia with Lewy bodies, Parkinson's disease with and without dementia, and Alzheimer's disease. Clin Neurol Neurosurg 2005; 107: 396-403.
37. Molloy SA, Rowan EN, O'Brien JT, McKeith IG, Wesnes K, Burn DJ. Effect of levodopa on cognitive function in Parkinson's disease with and without dementia and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 2006; 77: 1323-1328
38. Neufeld MY, Inzelberg R, Korczyn AD. EEG in demented and non-demented parkinsonian patients. Acta Neurol Scand 1988; 78: 1-5.
39. Nishino S, Ripley B, Overeem S, Nevsimalova S, Lammers GJ, Vankova J, et al. Low cerebrospinal fluid hypocretin (Orexin) and altered energy homeostasis in human narcolepsy. Ann Neurol 2001; 50: 381-388
40. Nishino S, Kanbayashi T. Symptomatic narcolepsy, cataplexy and hypersomnia, and their implications in the hypothalamic hypocretin/ orexin system. Sleep Med Rev 2005; 9: 269-310.
41. Ondo WG, Dat Vuong K, Khan H, Atassi F, Kwak C, Jankovic J. Daytime sleepiness and other sleep disorders in Parkinson's disease. Neurology 2001; 57: 1392-1396
42. Overeem S, van Hilten JJ, Ripley B, Mignot E, Nishino S, Lammers GJ. Normal hypocretin-1 levels in Parkinson's disease patients with excessive daytime sleepiness. Neurology 2002; 58: 498-499
43. Parrino L, Terzano MG. Polysomnographic effects of hypnotic drugs. A review. Psychopharmacology 1996; 126: 1-16.
44. Perneger TV. What's wrong with Bonferroni adjustments. Br Med J 1998; 316: 1236-1238
45. Ramirez-Ruiz B, Junque C, Marti MJ, Valldeoriola F, Tolosa E. Cognitive changes in Parkinson's disease patients with visual hallucinations. Dement Geriatr Cogn Disord 2007; 23: 281-288 (Pubitemid 46631933)
46. Riekkinen P, Buzsaki G, Riekkinen P Jr, Soininen H, Partanen J. The cholinergic system and EEG slow waves. Electroencephalogr Clin Neurophysiol 1991; 78: 89-96.
47. Roks G, Korf ESC, van der Flier WM, Scheltens P, Stam CJ. The use of EEG in the diagnosis of dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 2008; 79: 377-380
48. Rye D. Sleepiness and unintended sleep in Parkinson's disease. Curr Treat Options Neurol 2003; 5: 231-239
49. Schlösser R, Röschke J, Rossbach W, Benkert O. Conventional and spectral power analysis of all-night sleep EEG after subchronic treatment with paroxetine in healthy male volunteers. Eur Neuropsychopharmacol 1998; 8: 273-278
50. Shpirer I, Miniovitz A, Klein C, Goldstein R, Prokhorov T, Theitler J, et al. Excessive daytime sleepiness in patients with Parkinson's disease: a polysomnography study. Mov Disord 2006; 21: 1432-1438
51. Tandberg E, Larsen JP, Karlsen K. Excessive daytime sleepiness and sleep benefit in Parkinson's disease: a community-based study. Mov Disord 1999; 14: 922-927
52. Thannickal TC, Lai YY, Siegel JM. Hypocretin (orexin) cell loss in Parkinson's disease. Brain 2007; 130: 1586-1595
53. Thannickal TC, Lai YY, Siegel JM. Hypocretin (orexin) and melanin concentrating hormone loss and the symptoms of Parkinson's disease. Brain 2008; 131: e87.
54. Vendette M, Gagnon JF, Décary A, Massicotte-Marquez J, Postuma RB, Doyon J, et al. REM sleep behavior disorder predicts cognitive impairment in Parkinson disease without dementia. Neurology 2007; 69: 1843-1849
55. Wenzelburger R, Zhang BR, Pohle S, Klebe S, Lorenz D, Herzog J, et al. Force overflow and levodopa-induced dyskinesias in Parkinson's disease. Brain 2002; 125: 871-879
56. Yasui K, Inoue Y, Kanbayashi T, Nomura T, Kusumi M, Nakashima K. CSF orexin levels of Parkinson's disease, dementia with Lewy bodies, progressive supranuclear palsy and corticobasal degeneration. J Neurol Sci 2006; 250: 120-123